VictoryShares International Free Cash Flow Growth ETF (GRIN)
Live price chart, market sentiment, and community perspectives for VictoryShares International Free Cash Flow Growth ETF (NASDAQ: GRIN).
Live price chart, market sentiment, and community perspectives for VictoryShares International Free Cash Flow Growth ETF (NASDAQ: GRIN).
On our desk, GRIN looks like an interesting tactical play for international growth, but the plumbing concerns me. With an AUM hovering around $240M to $273M and a thin daily dollar volume of roughly $2,952, execution costs can sneak up on you if you try to scale in or out quickly. The strategy—screening for high free cash flow return on invested capital coupled with modified absolute momentum—is fundamentally sound and clearly working right now, as evidenced by its 1-year return outpacing the broader Foreign Large Growth category. However, I advise clients to treat it strictly as a small 5% to 10% portfolio diversifier rather than a core international holding until the liquidity profile deepens.
Watching the technicals and risk metrics, GRIN presents an interesting paradox. Its 1-year beta sits at 1.30, signaling materially higher sensitivity to market swings than the typical category beta of 0.90 to 1.10. Yet, Morningstar's 3-year and 5-year risk metrics show 'Low' risk versus category, reflecting a compressed history where the index managed drawdowns better than peers (-32.1% versus -36.8%). From a macro perspective, the fund concentrates heavily in European and Asian exporters across luxury, industrials, semiconductors, and healthcare, making it acutely sensitive to currency moves and real rate volatility. Investors need to be prepared for cyclical drawdowns in risk-off periods.
When analyzing the quantitative profile of GRIN, the separation between its total volatility and downside volatility caught my eye. The Sharpe ratio of 0.59 clears the basic hurdle for decent risk-adjusted return, but the Sortino ratio of 1.14 is nearly double that, indicating that downside volatility has been well-managed relative to its overall swings. Price action as of mid-2026 places it near $28.38, comfortably positioned between its 20-day and 50-day moving averages following a recovery from its August 2025 lows and below its February 2026 all-time high of $30.88. For systematic model builders, the rule-based, semi-active construction offers clean factor exposure, provided you account for the lack of a mature multi-year track record.
Explore plasma cleansing, somatic organ swaps, and BCI.